Konjac glucomannan hydrolysate was derived enzymatically from konjac flour under optimal conditions. A number of culture strains of lactobacilli and bifidobacteria were grown on De Man, Rogosa and Sharpe (MRS) media supplemented with the hydrolysate. This hydrolysate stimulated the growth of all strains examined. Colony sizes of those strains grown on konjac hydrolysate were significantly (P = 0.001) bigger than those grown on pectin or xylan hydrolysates. Bacterial growth profiles were also conducted on nutrient agar (MRS or modified MRS agar containing konjac hydrolysate) using single strains of lactobacilli or bifidobacteria (Lactobacillus acidophilus, Lactobacillus casei or Bifidobacterium adolescentis), single pathogen cultures (Escherichia coli or Listeria monocytogenes) or mixed bacterial cultures (from chicken breast extract). Although the growth of lactobacilli inhibited the growth of pathogens (single or mixed culture) the pathogens could not grow on the konjac hydrolysate as a sole carbon source. Microbial growth profiles using konjac hydrolysate or inulin in UHT milk were also investigated. The results showed that the numbers of colony forming units (cfu) obtained from milk containing the konjac hydrolysate were significantly (P = 0.01) higher than those containing inulin. It is suggested that the unique properties of konjac hydrolysate make it universally valuable as a prebiotic which can be applied to a wide range of foods, feeds and healthcare/pharmaceutical products

Summary Treatment of vaginal infection requires different drugs although the recurrence rate post treatment remains high due to adverse effects on the beneficial microbiota. Thus, there are clear clinical advantages for the use of biotherapeutic agents (prebiotics and/or probiotics) for treating these infections. Pre‐ and probiotic beneficial effects can be delivered topically or systemically. In general, both approaches have the potential to optimize, maintain and restore the ecology of the vaginal ecosystem. Specific carbohydrates provide a therapeutic approach for controlling infections by stimulating the growth of the indigenous lactobacilli but inhibiting the growth and adhesion of pathogens to the vaginal epithelial cells. Overall, little evidence exists to promote the prevention or treatment of vaginal disease with prebiotic carbohydrates in formulations such as pessaries, creams or douches. However, recent reports have promoted prebiotic applications in ecosystems other than the gut and include the mouth, skin and vagina. This review focuses on the utilization of pre‐ and probiotics for vaginal health.

No abstract

The synbiotic ability of probiotic bacteria and konjac glucomannan hydrolysates (GMH) to inhibit acne-inducing bacterium, Propionibacterium acnes growth was studied in vitro. All probiotic bacteria strains tested were able to inhibit the growth of this species of skin bacterium where the inhibition was significantly (P < 0.01) enhanced by the presence of the GMH prebiotic. As the current treatment of acne is based on topical or systemic drugs, it is worth examining further the biotherapeutic activities of the GMH and selected probiotics with a view to future use as prophylactic or therapeutic synbiotics for treating acne infections.

Purpose - The aim of this study is to determine the effects of depolymerised mannans and specifically konjac glucomannan hydrolysates (GMH) on the colonic microflora of mice. Blood glucose and cholesterol were also measured. Design/methodology/approach - Two groups (n?=?20) of 12-week old Wister mice were used for a period of 14 weeks. One group (treatment group) were fed diets containing 5 per cent konjac GMH dissolved in drinking water in addition to the control (group) standard diet. Faecal microflora, feed consumption, body weight, blood glucose and cholesterol were determined. Findings - The GMH promoted the growth of anaerobes and lactobacilli in the treatment group where this was statistically, highly significant (P?